There are a number of mitochondrial rejuvenation therapies that are being pursued by big and small pharma. Below, I wanted to give an overview of the little I was able to find and very much hope that someone else can help in digging out more information on these.
https://shiftbioscience.com/
These guys are very much focused on a single drug:
In pre-clinical studies we have confirmed the ability of SB200 – our lead candidate therapeutic molecule – to reverse mitochondrial dysfunction in fibroblasts sourced from a variety of donors.
The first clinical application of our therapeutic will be rare mitochondrial diseases, including MELAS, MERRF and NARP. Beyond this, we are also exploring its use as a therapeutic for other age-related diseases.
Thing is, I am finding nothing at all about SB200. In some studies silibinin is referred to as SB200. Example:
https://mct.aacrjour...ontent/10/1/104
Thing is, I am finding nothing at all about SB200. In some studies silibinin is referred to as SB200. Example:
https://mct.aacrjour...ontent/10/1/104
Cells were treated with 200 μM of silibinin (SB-200) and/or 80 μM of z-VAD-fmk for 48 hours; in combination treatment, z-VAD-fmk was added 1 hour prior to silibinin treatment. At the end of treatment, the cells were analyzed for apoptosis by flow cytometry
What the hell? Silibilin is the major active in Silymarin. Is Shift Biosciences simply trying to patent a known substance that is a plant extract? Shouldn't be really. Any ideas?
..................................................................................................
These guys are a whole lot more advanced and come across much more credible
Kinase-targeted drugs have been in development for more than thirty years and have made a large impact on the way we treat many human diseases. The great majority of these drugs work by inhibiting kinases – ie, reducing or eliminating their signaling activity. Mitokinin is taking a different approach to targeting kinases: we aim to increase the activity of active-form PINK1.
Mitokinin’s lead candidate, MTK-458, has been extensively validated in in vitro and in vivo models of Parkinson’s disease. IND enabling studies are currently underway, and an IND filing is expected in 2020. In parallel, Mitokinin’s scientists are also investigating the activity of MTK-458 in models of Huntington’s disease, Alzheimer’s disease, and non-CNS diseases of aging where mitochondrial dysfunction is implicated.
......................................................................................
Very fluffy really. Cannot find a drug name
712 North is a pre-clinical stage pharmaceutical company based in California. We develop modulators of the dynamic mitochondrial network for a range of age-related diseases such as Alzheimer's, cancer, glaucoma, and cardiovascular disease. The mechanism of action ties the biology also to a rare pediatric indication with unmet medical need. We can leverage this orphan disease as fast to market strategy. Our goal is to become the global leader in innovative personalized mitochondrial medicines.
OK, so let's see if the above sparks some interest...
